Standout Papers

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with... 2017 2026 2020 2023 379
  1. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer (2017)
    Stephen Bagley, Shawn Kothari et al. Lung Cancer

Immediate Impact

3 by Nobel laureates 3 from Science/Nature 61 standout
Sub-graph 1 of 24

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
3 intermediate papers

Works of Beth Eaby‐Sandy being referenced

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
2017 Standout

Author Peers

Author Last Decade Papers Cites
Beth Eaby‐Sandy 644 320 199 11 916
Christine B. Boers‐Doets 418 362 192 19 772
Pamela Lockbaum 758 220 56 13 973
E Silverberg 414 317 28 8 958
Robert R. Carroll 690 182 96 14 879
Peter C. Ungaro 460 244 48 12 778
Jean Pierre Delord 501 183 109 20 769
F. Asrari 394 214 88 23 831
Jin-Hyuk Choi 423 733 72 18 1.1k
Annette Østergaard Jensen 587 306 169 22 1.1k
S W McCarthy 532 201 82 20 859

All Works

Loading papers...

Rankless by CCL
2026